Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Healthcare services beat-and-raise candidate: Q1 2026 revenue and adjusted EPS beat estimates, full-year guidance was raised, VITAS growth remained strong with admissions up 6.9%, and the company added a new $300M buyback authorization.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Breakout held ⢠Near resistance Support Level: $500.00 Resistance Level: $513-$514 Over the last month, CHE has maintained a constructive uptrend with higher lows and a breakout above $500, but momentum has paused near $513-$514 resistance and a drop below $503-$504 would weaken the setup.
Sentiment & News
Key News Insights: ⢠VITAS Growth ⢠Roto-Rooter Lift ⢠Cost Headwinds Chemed's outlook remains constructive with VITAS/Roto-Rooter improvements and an upcoming Q2 earnings release as catalysts, though inflation, tariffs and competition continue to weigh on near-term execution.
AI Summary
CHE remains a high-quality defensive operator, but with sales growth and returns on capital still soft and the stock already priced for resilience, the key takeaway is that upside now depends on clear execution and Q2 confirmation while any âgood but not betterâ print could trigger valuation compression.
Description
Chemed Corporation delivers hospice and palliative care through a multidisciplinary network of clinicians, aides, social workers, clergy and volunteers across the United States under its VITAS segment, and provides plumbing, drain, excavation and water-restoration services to residential and commercial customers via company branches, independent contractors and franchisees under its Roto-Rooter segment. The company operates these two distinct businesses from its headquarters in Cincinnati and has been incorporated since 1970.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 28 | May 5 | CHE | Chemed Corporation | Healthcare services beat-and-raise candidate: Q1 2026 revenue and adjusted EPS beat estimates, full-year guidance was raised, VITAS growth remained strong with admissions up 6.9%, and the company added a new $300M buyback authorization. | Closed | +1.5% |